A method of managing treatment in a patient with B-cell acute lymphoblastic leukemia (B-ALL) for central nervous system (CNS) leukemia is disclosed. The method comprises obtaining cerebrospinal fluid (CSF) from the patient, obtaining a cell proteome including PFDN5-α from the patient, detecting reactivity of CSF against the PFDN5-α, comparing reactivity profile of CSF against the PFDN5-α at diagnosis and during treatment, and determining the status of proliferation of leukemia in the patient depending on the comparison. The method further comprises treating the patient for CNS leukemia based on the status of proliferation.
K. Kumar N. . Menon, Xavier, T., and HARIDASAN, A., “Differential cerebrospinal fluid reactivity to pfdn5-alpha for detection of b-cell acute lymphoblastic leukemia”, U.S. Patent 15 / 314 , 4912019.